INVESTORS

Press Releases

Year

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

- Launched Exclusive In Vivo Gene Insertion Collaboration with Novartis to Develop Single ARCUS Nuclease as Potential One-time Hemoglobinopathy Treatment - Extended Cash Runway to End of 2024 - Reported Updates Across Allogeneic CAR T Pipeline; Interim Results from Lead PBCAR0191 Study with CAR T...

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

August 1, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 25, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 25, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on July 19, 2022 , the Compensation Committee of Precision’s...

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

June 27, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224...

Precision BioSciences Announces $50 Million Offering of Common Stock

June 21, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a...

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

June 21, 2022

- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - Precision to Develop a Single ARCUS ® Nuclease Designed for Safe and Efficient In Vivo Gene Insertion -...

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

June 8, 2022

PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects PBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable Responders...

Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022

June 3, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T...

Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference

June 3, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Healthcare...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2022

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022 , respectively...

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 11 - 20 of 31

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies